CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 242 enrolled / 242 target
Drug / intervention
Nemolizumab +1 moredrug
Likely dose
60 milligramfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04365387
NCT04365387Phase 2CompletedMonitor (3.2/mo)Completion was 35mo ago
CompareCT.gov

A Randomized, Double-Blind, Placebo-Controlled Study to Assess Immunization Responses in Adult and Adolescent Subjects With Moderate-to-Severe Atopic Dermatitis Treated With Nemolizumab

Galderma R&D·interventional·Posted Apr 28, 2020·Updated Jun 1, 2026

In Brief

A Phase 2 clinical trial evaluating Nemolizumab and Placebo for Dermatitis, Atopic. Completed, enrolled 242 participants across 64 sites.

Signals

Enrolling slower than its timeline implies

Detailed Summary

The purpose of this study is to assess the effect of nemolizumab (CD14152) on humoral immune responses to tetanus and meningococcal vaccination in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDermatitis, Atopic
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedApr 28, 2020
Enrollment StartMar 5, 2020
Primary CompletionJul 7, 2023
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 6.2 years ago

Arms & Interventions

Nemolizumabexperimental

Participants received a loading dose of nemolizumab (60 milligram \[mg\]) via 2 subcutaneous (SC) injections at baseline. Nemolizumab (30 mg) was administered via a single subcutaneous injection every 4 weeks (Q4W) at Weeks 4, 8, and 12.

Drug: Nemolizumab
Placeboplacebo_comparator

Participants received a placebo via 2 SC injections at baseline. Placebo was administered via a single subcutaneous injection Q4W at Weeks 4, 8, and 12.

Drug: Placebo

Interventions

Nemolizumabdrug

Nemolizumab was administered by 2 SC injections as 60-mg loading dose at baseline and a single 30-mg dose at Weeks 4, 8, and 12.

Placebodrug

Placebo was administered by 2 SC injections at baseline and a single dose at Weeks 4, 8, and 12.